OTLK - Spark Newswire

5 minute read

Outlook Therapeutics Submits Biologics License Application To FDA For ONS-5010 As A Treatment For Wet AMD

Today, 4:32 PM

ONS-5010 / LYTENAVA™ (bevacizumab-vikg), if approved, expected to receive 12 years of marketing exclusivity ISELIN, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics,

OTLK

2 minute read

4 Penny Stocks Insiders Are Buying

By Lisa Levin

Today, 4:32 PM

US crude oil futures traded higher by around 4% on Friday. Investors, meanwhile, focused on some notable insider trades When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

ACHR

2 minute read

4 Penny Stocks Insiders Are Buying

By Lisa Levin

Today, 4:32 PM

China’s official NBS manufacturing PMI rose to 50.2 in February from January's figure of 50.1. Investors, meanwhile, focused on some notable insider trades

AVTX

1 minute read

Outlook Therapeutics: Q1 Earnings Insights

By Benzinga Insights

Today, 4:32 PM

Outlook Therapeutics (NASDAQ:OTLK) reported its Q1 earnings results on Monday, February 14, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

OTLK

4 minute read

General

Outlook Therapeutics Provides A Corporate Update And Business Outlook

By Bill Haddad

Today, 4:32 PM

Outlook Therapeutics advancing first ever ophthalmic formulation of bevacizumab towards new U.S. FDA Biologics License Application (BLA) submission, anticipated this quarter ONS-5010 / LYTENAVA™

OTLK

1 minute read

Recap: Outlook Therapeutics Q4 Earnings

By Benzinga Insights

Today, 4:32 PM

Outlook Therapeutics (NASDAQ:OTLK) reported its Q4 earnings results on Wednesday, December 22, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

OTLK

1 minute read

Outlook Therapeutics FY21 EPS $(0.35) Up From $(0.67) YoY

By Benzinga Newsdesk

Today, 4:32 PM

Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.35) per share. This is a 47.76 percent increase over losses of $(0.67) per share from the same period last year.

OTLK

4 minute read

The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares

By Shanthi Rexaline

Today, 4:32 PM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ABBV

2 minute read

4 Penny Stocks Insiders Are Buying

By Lisa Levin

Today, 4:32 PM

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

AESE

2 minute read

5 Penny Stocks Insiders Are Buying

By Lisa Levin

Today, 4:32 PM

ARC

Feed Symbols: OTLK